Merck Digital Sciences Studio

Merck Digital Sciences Studio

Merck Digital Sciences Studio opened applications in March 2022 under the leadership of Robert K. Coughlin, former head of JLL's life sciences practice, and Isaac Barchas of Austin's Capital Factory. The program was created in partnership with the New Jersey Innovation Institute, a New Jersey Institute of Technology corporation, and Microsoft for Startups. Rather than operating as a conventional corporate venture capital arm or a standalone office, the Studio functions as a 10-month accelerator designed to place early-stage companies inside Merck's discovery and development workflows. The Studio invests in up to 12 seed-stage companies annually across two cohorts, targeting technologies that can make drug discovery and clinical development faster and more efficient. Each accepted startup receives an initial investment of up to $120,000 and access to $250,000 in Microsoft Azure cloud credits. The program is structured around three core pillars: artificial intelligence and machine learning applications for drug design, digital health platforms that enhance clinical trial execution, and enterprise software tools that improve pharmaceutical R&D operations. The geographic footprint spans Newark, NJ (the operating home base), with additional programming and mentoring hubs in Boston, Durham, and London. Total deployment capacity is defined by cohort size rather than a traditional fund structure. The Studio is supported by a network of collaborators including TechSquare Labs, which provides cohort programming, and a mentor roster drawn from Merck research leadership. There is no disclosed AUM or fund vehicle; the entity commits balance-sheet capital directly into each startup. In April 2023, the first cohort of 12 companies graduated, having focused on areas including AI-enabled small-molecule design, decentralized clinical trial platforms, and real-world evidence generation. Merck has not disclosed a subsequent fundraise or external LP base, keeping the initiative housed within the corporation's broader innovation ecosystem. What distinguishes the Studio structurally is its data-access model. Unlike most corporate accelerators that offer mentorship and workspace, Merck gives cohort companies selective access to proprietary, de-identified Merck datasets for training and validating algorithms. This creates a genuine technical moat for participants — and a filter for Merck — that a purely financial accelerator cannot replicate. The program's hybrid position, straddling an internal R&D enabler and an external startup investor, means its success is measured by both portfolio company outcomes and the volume of tools adopted back into Merck's discovery pipeline.